Aims/hypothesis The effect of n-3 fatty acid treatment on temperature perception as a sensory nerve function modality is uncertain. In patients with non-alcoholic fatty liver disease (NAFLD) both with and without type 2 diabetes, we: (1) tested whether 15-18 months' treatment with 4 g/day of docosahexaenoic plus eicosapentaenoic acid (DHA+EPA) improved hot (HPT) and cold (CPT) temperature perception thresholds and (2) explored factors associated with HPT and CPT, in a randomised, double-blind, placebo-controlled trial. Methods The effect of treatment (n = 44) on HPT, CPT and temperature perception index (TPI: difference between HPT and CPT) was measured at the big toe in 90 individuals without neuropathy (type 2 diabetes; n = 30). Participants were randomised 1:1, using sequential numbering, by personnel independent from the trial team. All participants and all members of the research team were blinded to group assignment.
Introduction
Small sensory nerve fibre neuropathies (SFSN) give rise to the symptoms of impaired nerve sensitivity and neuropathic pain which affect over 90% of people with type 1 and type 2 diabetes [1, 2] and are the main initiating factors for foot ulceration and lower limb amputation in people with diabetes [3] . The mechanisms underlying SFSN and neuropathic pain are not well understood but may include metabolic factors such as elevated intracellular glucose levels in both vascular and neural tissues, which can lead to increased oxidative stress and/or microvascular impairment and reduced nerve blood flow [4, 5] . Quantitative sensory testing (QST) is a method for assessing the somatosensory nervous system and is routinely used in the clinical assessment of large and small sensory nerve fibre function [6, 7] . We have recently shown using QST of large myelinated nerve function that both ageing and a measure of microvascular reactivity were independently associated with altered vibration perception threshold (VPT) at 125Hz in a high-risk patient group without evidence of overt peripheral neuropathy [8] . QST has also been used to study functional deficits in small fibre neuropathies, with temperature perception thresholds being one of the more widely employed tests [9] [10] [11] . Such tests provide an indirect but reproducible assessment of human small nerve function [12, 13] .
There are as yet no treatments that prevent or reverse painful diabetic neuropathy. Vasodilator sprays may improve nerve blood flow [14] and alpha lipoic acid [15] (as a sulphur-containing product derived from the eight-carbonatom fatty acid octanoic acid) has been shown to give moderate pain relief in clinical trials, with fewer side effects than opioids and antidepressants [16] . Treatment with highdose long-chain polyunsaturated n-3 fatty acids such as eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3) has been shown to improve vibration perception and clinical symptoms of neuropathy in patients with type 2 diabetes [17] and to improve endothelial function in dyslipidaemia, overweight men [18] , as well as offering neuroprotection by increasing nerve blood flow in an experimental model of diabetic neuropathy [19] . However, the benefit of long-chain n-3 fatty acids in patients at risk of, but without peripheral neuropathy, remains uncertain.
In a pre-specified sub-study of the Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy (WELCOME) trial (ClinicalTrial.gov registration no. NCT00760513) [20, 21] (a randomised doubleblind placebo-controlled trial), we tested the effect of DHA+ EPA (Omacor/Lovaza) treatment on hot and cold temperature perception thresholds. Our overall aim was to test the hypothesis that the highest licensed dose of DHA+EPA n-3 fatty acid treatment (4 g/day as ethyl esters) over a minimum of 15 months and a maximum of 18 months had beneficial effects on small sensory nerve function in high-risk patients for neuropathy, who had insulin resistance and non-alcoholic fatty liver disease (NAFLD) (with or without type 2 diabetes).
Methods

Study design
The participants formed part of the WELCOME study and the investigations were approved by the local research ethics committee (REC: 08/H0502/165) [20, 21] . One hundred and five individuals were recruited to the study (see Electronic Supplementary Material [ESM] Fig. 1 for the consort diagram and testing the effect of the intervention on this secondary endpoint). Participants were excluded from the current analysis if they had evidence of distal peripheral neuropathy in their feet, as suggested by their failure to detect a 10 g monofilament [22] (n = 4), or if they had evidence of diabetic eye disease at retinal screening (n = 0). Baseline and end of study thermal thresholds were obtained on 90 individuals (53 men and 37 women; mean age of 50.9 ± 10.6 years) of whom 44 were on active treatment and 46 on placebo. Participants gave their informed written consent. Biochemical and anthropometric measurements have been described previously [8] .
Peripheral neurological and microvascular function testing
All tests were conducted in a temperature controlled room (22-24°C) as described previously [8] . Participants refrained from caffeine-containing drinks, smoking and exercise for ≥2 h prior to testing. Measurements were made at baseline and end of study.
Temperature perception testing Hot (HPT) and cold (CPT) temperature perception thresholds were measured on the pulp of the left big toe using a thermal aesthesiometer (HVLab Diagnostics Instruments, Southampton, UK) [23] (see ESM Methods for details). A threshold temperature perception 'index' (TPI) was constructed for each individual, calculated as the arithmetic difference between HPT and CPT (°C) measured at baseline [24] .
Vibrotactile perception testing VPTs at 125 Hz were measured on the pulp of the left big toe as described previously [8] (see ESM Methods for details). 
Statistical analysis
Statistical analyses were undertaken using IBM SPSS Statistics 21.0 (IBM UK). Pearson and Spearman rank correlation coefficients were used to investigate associations between normally and non-normally distributed variables, respectively. In all cases a value of p < 0.05 was taken to indicate significance. Multivariable linear regression modelling was used to test the independence of associations between baseline variables and baseline measurements of HPT, CPT and TPI. Explanatory factors that were included in the regression models included age, sex, diabetes (yes/no) (or HOMA-IR), measures of body fat and MF/RF. In additional analyses we also tested for effects of medications and skin temperature. We also tested the effects of DHA+EPA treatment on TPI and both HPT and CPT using multivariable linear regression modelling. For all three outcomes of interest the outcome represented the 'change' variable, i.e. the difference between the end of study measurement and the baseline study measurement. For each separate regression model, there was also adjustment for the baseline measurement of the respective outcome variable in question. Each of these models included DHA+EPA treatment as a dichotomous exposure variable age, sex, the temperature threshold variable at baseline (of the respective outcome variable) and additional relevant exposures of interest, selected from the univariable analyses (including total body fat %, MF/RF, and diabetes status (yes/no) or insulin resistance (HOMA-IR)). Table 1 shows the baseline characteristics of the participants without overt neuropathy or microvascular disease. Of the participants, 35 were treated with statins, 32 with antihypertensive drugs, seven with fibrates, 18 with ACE inhibitors (ACEI), 24 with metformin and 13 with antidepressants.
Results
Characteristics of the group
Effect of the n-3 polyunsaturated fatty acid intervention on temperature perception thresholds Individual baseline and end of study measurements for HPT, CPT and TPI for participants are shown in Fig. 1 . Table 2 shows the results of multivariable regression modelling testing the effects of the DHA+EPA intervention on the change in HPT, CPT and TPI (i.e. the change between the end and start of the study) and shows no effect of the treatment on each of the outcomes of interest. Swapping HOMA-IR for diabetes status had little effect on the models.
Associations between HPT and CPT and cardiovascular and metabolic risk factors at baseline
In univariate analyses (see ESM for table of univariate analyses showing associations between hot and cold temperature perception thresholds and cardiovascular and metabolic risk factors at baseline), both HPT and CPT were associated with sex (r = −0.252 p = 0.017 and r = 0.244 p = 0.021, respectively), with women being more sensitive to the thermal stimuli than men. HPTs and CPTs were associated with total body fat percentage and subcutaneous abdominal fat quantity. The associations between HPT and CPT measured at the big toe and percentage body fat were independent of skin temperature (mean skin temperature measured at the big toe prior to testing was 28.2 ± 2.5°C (n = 90)) and were not affected by adjustment for skin temperature. Scatter plots for the association between HPT and CPT and body fat are shown in Fig. 2 . The direction of the correlations shows that temperature perception (or the ability to detect the stimulus after a small temperature change) increases with increasing total body fat percentage. TPI showed a similar association with total body fat percentage (r = 0.39, p = 0.0001) (Fig. 2) with the direction of correlation showing a reduction in TPI with increasing body fat. Similar trends were seen at the left middle finger (data not shown).
There was no significant association between HPT and CPT and measures of glycaemic status (fasting glucose concentration or HbA 1c , participants with or without diabetes) or insulin resistance (HOMA-IR, participants without diabetes). In individuals with diabetes (n = 30), HPT was associated with the duration of diabetes (r = 0.471, p = 0.009), but CPT was not (r = −0.267, p = 0.154).
HPT was associated with CPT (r = −0.670, p < 0.0001), a finding consistent with that in a cohort of 300 healthy students [25] . Temperature perception was also associated with VPT measured at 125 Hz at the big toe [8] (HPT r = 0.326, p = 0.002; CPT r = −0.211, p = 0.046).
Using regression modelling, we explored the independence of associations between HPT, CPT and TPI and each of the variables that were shown to be associated with these outcomes in the univariate analyses. HPT, CPT and TPI were the respective outcomes in these separate regression models (Table 3) . These multivariable models showed that the exposure variables in the models explained 21% of the variance in HPT, 18% in CPT and 23% of the variance in TPI. Of note, in each of these regression models there was a strong independent association between total body fat percentage and HPT, CPT and TPI. Swapping HOMA-IR for diabetes status had little effect on each regression model (data not shown). Use of statins, fibrates, metformin, antidepressants or all antihypertensive drugs (including calcium antagonists and ACEIs) was not independently associated with thermal perception thresholds when each factor was added to the model as a dichotomous exposure variable (data not shown).
Discussion
Our novel results show no benefit from DHA+EPA treatment on hot or cold temperature perception thresholds, in patients with NAFLD, both with and without diabetes. We have examined the effects of the highest licensed dose of n-3 fatty acids (4 g/day as Omacor/Lovaza) on measures of small sensory nerve fibre function in a randomised double-blind placebo-controlled trial lasting a minimum of 15 months and a maximum of 18 months in participants at risk of developing diabetic neuropathy and neuropathic pain. To our knowledge, our study is the first randomised double-blind placebo- Data are presented as mean ± SD or median (interquartile range) a NAFLD fibrosis score, see reference [36] controlled trial to examine the effects of DHA+EPA on temperature perception. We also show for the first time that hot and cold thermal perception thresholds were strongly and independently associated with total body fat percentage (but not with liver fat or with glycaemic control) in men and women.
We found no association between hot or cold temperature perception thresholds and measures of insulin sensitivity or HbA 1c in these patients who were at risk of neuropathy. Our findings are consistent with the results of a study of 156 individuals with peripheral neuropathy where there was no association between neuropathy and glycaemic control [26] . Elevated hot thresholds have been shown to be the most frequent sensory deficit in individuals with diabetes and hot thresholds have been shown to be correlated with glycaemic control in some [9, 27] but not all [28, 29] studies. In those individuals with diabetes, HPT was associated with duration of diabetes, possibly due to increased oxidative stress, nerve damage or reducing nerve fibre densities that are early events in people with diabetes [30] . We also observed correlations between hot and cold temperature perception thresholds and total body fat percentage measured by dual energy x-ray absorptiometry (DXA), and with abdominal subcutaneous fat assessed using MRI. Surprisingly, the directions of these associations indicate that thermal sensitivity (or the ability to detect the stimulus with a small temperature change) increased as the proportion of body fat increased. Importantly, these associations were independent of sex and of age [31] . Temperature thresholds depend on the contact area between the skin and the warm or cool surface with greater sensitivity when more receptors are excited by a larger contact area [32] . It is possible that increased subcutaneous fat resulted in an increased area of contact between the surface of the thermal aesthesiometer and the big toe but it was not possible to adjust for the size of the big toe in this study. The changes in temperature perception thresholds may alternatively be associated with skin thickness and thermal conduction and/or nerve density and tissue blood flow but investigation of these factors was beyond the scope of the present study. Obesity is characterised by a low-grade chronic inflammatory state, which is known to modulate pain, and people with chronic pain tend to have a greater total fat mass [33] . Thus it is possible that the increase in temperature sensitivity with increasing body fat percentage that we observe in our cohort may to be due to a change in small sensory nerve fibre function modulated by an increased release of pro-inflammatory cytokines or adipokines from adipose tissue.
The current study extends previous data suggesting that the functions of both small and large sensory fibres are impaired in neurologically asymptomatic individuals both with and without diabetes. The temperature perception thresholds to hot and cold stimuli associated with activation of small sensory afferent A-delta and C-nerve fibres that we measured at the big toe were strongly correlated with large sensory nerve fibre VPT measured at 125Hz [8] . Large-fibre nerve dysfunction measured by VPT predicts foot ulceration, lower limb amputation and mortality [26] . However, to what extent assessment of small fibre function using QST may represent an additional screening tool to monitor disease progression and therapeutic impact remains uncertain [34] .
Limitations
QSTs are psychophysical tests and their use as a diagnostic tool alone or in combination with other more direct tests is much debated [34] . We cannot overlook the fact that there are a number of factors that may affect temperature perception thresholds which we have been unable to measure, including alertness and attention, integration of sensory information from the stimulated skin area and skin thickness [25] . Our results provided no indication of an improvement with the intervention (Table 2) . A retrospective power calculation based on a sample size of n = 90 with n = 44 in the treatment arm of the trial shows that we had 84% power to detect a 3.5°C temperature difference in HPT between baseline and the end of study with DHA+EPA treatment. That we observed only a 1°C mean temperature difference in HPT between baseline and end of study in the treatment arm, strongly suggests that there was no effect of the intervention on this variable but we would have needed a ten times bigger sample size to prove there was no effect of treatment. Additionally, with the very low CV (~6%) of the temperature perception threshold measurement techniques, this gives us further confidence in the validity of the findings. It is interesting to note that there was no worsening of temperature perception thresholds in the placebo arm of the trial. This finding is consistent with both the results of our previous study investigating the effect of the DHA+EPA intervention on VPTs as a measure of large sensory nerve fibre function [8] and the results of others [35] ; and it is plausible that the duration of our trial (a minimum of 15 months and a maximum of 18 month) was insufficient for us to demonstrate a deterioration in temperature perception thresholds. Finally, we cannot be sure of the effect of duration of diabetes on temperature perception in our cohort, as identification of the date of onset of type 2 diabetes is often imprecise in clinical practice.
Conclusions
In summary, treatment with the highest licensed dose of DHA+EPA (as Omacor/Lovaza) did not modify small nerve fibre-mediated temperature perception in patients with NAFLD both with and without diabetes. In this high-risk patient group, without evidence of overt peripheral neuropathy, percentage body fat was independently associated with HPT and CPT. Both HPT and CPT were more strongly associated with the measure of overall body fatness than with any metabolic risk factors.
